68Ga-DOTATATE Neuroblastoma Imaging Pilot
Key facts
- Where
- Montreal és Sherbrooke, KanadaSee the 3 sites
- Phase
- 2. fázis
Where in Kanada
- CHU Ste-JustineMontreal, KanadaTaking people
- McGill University Health Center - Children's hospitalMontreal, KanadaNo longer taking part
- CIUSSS de l'Estrie- CHUS HospitalSherbrooke, KanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Trial code
- NCT04559217
- Record updated
- 2026. május 27.
- Original description
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.Read full original descriptionShow less
Pilot Study of 68Ga-DOTATATE PET/CT and 123I-MIBG Scintigraphy Imaging of Neuroblastoma
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.
Inclusion: Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma; Planned 123I-MIBG imaging; Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent/legal tutor of the pediatric candidates); Aged between 1 day and 21 years old (inclusively).
Exclusion: Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan; Prior allergic reaction to somatostatin analogues; History of another cancer in the past 5 years other than non-melanomatous skin cancer; Currently under a randomized control trial with unknown allocation; Currently under treatment; Medically unstable or unable to undergo scan; Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).